29 March 2019
Disposal update, Timing of Full Year Results, Board Changes and Availability of the Circular…
Chesnara has continued to deliver significant cash generation, funding the dividend strategy as well as strengthening the group solvency ratio, despite the challenging economic backdrop in 2018. Economic Value was however impacted by the adverse economic conditions, though this was in line with sensitivities….
Somero announces that on Thursday, 28 March 2019, it approved the settlement of Restricted Stock Units (RSUs) for John Yuncza, Executive Director as well as non-executive, non-director managers eligible under the Somero 2010 Equity Incentive Plan….
Final Results for the year ended 31 January 2019…
AstraZeneca announces today its intention to raise up to approximately $3.5bn (the Placing Proceeds) through a placing of new ordinary shares in the Company (Placing Shares) with both existing and new institutional investors (the Placees) (the Placing)….
AstraZeneca has entered into a global development and commercialisation collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment….
28 March 2019
Director/PDMR Shareholding…
Johnson Matthey achieves two major milestones in commercialisation of eLNO®…